{
    "info": {
        "nct_id": "NCT06477419",
        "official_title": "Phase 2 Study of Sacituzumab Govitecan-hziy in Patients With Previously Treated Mesothelioma",
        "inclusion_criteria": "* Patient, or legally authorized representative (LAR), willing and able to provide written informed consent for the trial\n* Patient age ≥ 18 at time of consent\n* Pathologically confirmed diffuse pleural mesothelioma\n* Must have received at least one prior systemic therapy (platinum/pemetrexed, immunotherapy or a combination thereof)\n* Measurable disease as defined primarily by the modified RECIST criteria for mesothelioma (at PI discretion RECIST v1.1 may be used)\n* Consent to undergo a biopsy prior to Cycle 1 Day 1 and Cycle 3 Day 1 if deemed medically safe and feasible\n* Eastern Cooperative Oncology Group (ECOG) score 0 or Karnofsky Performance Status ≥ 70%\n* Adequate organ function, defined as\n\n  * Absolute neutrophil count ≥ 1.5K/mcL\n  * Platelet count ≥ 100K/mcL\n  * Adequate renal function defined as creatinine clearance ≥ 30ml/min (as calculated by Cockcroft-Gault Formula)\n  * Hemoglobin > 9g/dL (prior transfusion permitted if not within 7 days of enrollment)\n  * Total bilirubin ≤1.5 x upper limit of normal (ULN) if no liver metastases or <3 × ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases; subjects with Gilbert's syndrome can enroll if conjugated bilirubin is within normal limits\n  * AST, ALT ≤ 2.5 x ULN (if liver metastases are present, ≤5 × ULN)\n* If of childbearing potential, must be willing to use highly effective mode of contraception for at least one month prior, during, and for 2 months after the end of active therapy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Currently participating in another study and receiving another study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 3 weeks of the first dose of treatment\n* Prior hypersensitivity to irinotecan or any components of sacituzumab govitecan-hziy\n* Prior cytotoxic/immunologic systemic therapy within 3 weeks prior to study Day 1 or has not recovered (i.e., CTCAE v5 ≥ Grade 1 at baseline; from clinically significant adverse events due to a previously administered agent (excluding Grade 2 neuropathy)\n* Known psychiatric or substance abuse disorders that would interfere with the requirements of the trial within the opinion of the investigator\n* Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, early stage prostate cancer, or in situ cervical cancer after definitive treatment\n* Positive hepatitis B (hepatitis B virus [HBV]) surface antigen (HBsAg)\n\n  o NOTE: Subjects with a prior history of HBV demonstrated by positive hepatitis B core antibody are eligible if they have at Screening 1) a negative HBsAg and 2) a HBV DNA (viral load) below the lower limit of quantification, per local testing. Patients who fit these criteria must use Hep B prophylaxis during treatment. Subjects with a positive HBsAg due to recent vaccination are eligible if HBV DNA (viral load) is below the lower limit of quantification, per local testing\n* Positive hepatitis C antibody (anti-HCV)\n\n  o NOTE: Subjects with a prior history of HCV, who have completed antiviral treatment and have subsequently documented HCV RNA below the lower limit of quantification per local testing are eligible\n* Participant is positive for human immunodeficiency virus (HIV), with 1 or more of the following:\n\n  * Receiving ART that may interfere with study treatment (consult sponsor for review of medication prior to enrollment)\n  * CD4 count < 350 cells/mm3 at screening\n  * AIDS-defining opportunistic infection within 6 months of start of screening\n  * Not agreeing to start ART and be on ART > 4 weeks plus having HIV viral load <400 copies/mL at end of 4-week period (to ensure ART is tolerated and HIV controlled)\n* Myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), or coronary/peripheral artery bypass graft, or any acute coronary syndrome within 6 months of start of study drug\n* Congestive heart failure defined as New York Heart Association (NYHA) Class III-IV or hospitalization for congestive heart failure (any NYHA class) within 6 months of study Day 1\n* Pregnant women or women who are breastfeeding or of childbearing potential and not using a highly effective method of birth control for at least one month prior to enrollment. If the risk of contraception exists, male and female subjects must use highly effective contraception throughout the study and for at least 60 days after last treatment. Highly effective contraception includes either 2 barrier methods (diaphragm, condom by the partner, copper intrauterine device, sponge, or spermicide), or 1 barrier method and 1 hormonal method (any oral, subcutaneous, intrauterine, or intramuscular registered and marketed contraceptive agent that contains an estrogen and/or a progesterone agent)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Pathologically confirmed diffuse pleural mesothelioma",
            "criterions": [
                {
                    "exact_snippets": "Pathologically confirmed diffuse pleural mesothelioma",
                    "criterion": "diffuse pleural mesothelioma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathologically confirmed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient, or legally authorized representative (LAR), willing and able to provide written informed consent for the trial",
            "criterions": [
                {
                    "exact_snippets": "Patient, or legally authorized representative (LAR), willing and able to provide written informed consent for the trial",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": "written"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patient, or legally authorized representative (LAR)",
                    "criterion": "consent provider",
                    "requirements": [
                        {
                            "requirement_type": "allowed_providers",
                            "expected_value": [
                                "patient",
                                "legally authorized representative (LAR)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count ≥ 100K/mcL",
            "criterions": [
                {
                    "exact_snippets": "Platelet count ≥ 100K/mcL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mcL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) score 0 or Karnofsky Performance Status ≥ 70%",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) score 0",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "=",
                                "value": 0,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Karnofsky Performance Status ≥ 70%",
                    "criterion": "Karnofsky Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* AST, ALT ≤ 2.5 x ULN (if liver metastases are present, ≤5 × ULN)",
            "criterions": [
                {
                    "exact_snippets": "AST, ALT ≤ 2.5 x ULN (if liver metastases are present, ≤5 × ULN)",
                    "criterion": "AST level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST, ALT ≤ 2.5 x ULN (if liver metastases are present, ≤5 × ULN)",
                    "criterion": "ALT level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "if liver metastases are present, ≤5 × ULN",
                    "criterion": "AST level (with liver metastases)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "if liver metastases are present, ≤5 × ULN",
                    "criterion": "ALT level (with liver metastases)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient age ≥ 18 at time of consent",
            "criterions": [
                {
                    "exact_snippets": "Patient age ≥ 18 at time of consent",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin > 9g/dL (prior transfusion permitted if not within 7 days of enrollment)",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin > 9g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prior transfusion permitted if not within 7 days of enrollment",
                    "criterion": "prior transfusion",
                    "requirements": [
                        {
                            "requirement_type": "time since last transfusion",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Consent to undergo a biopsy prior to Cycle 1 Day 1 and Cycle 3 Day 1 if deemed medically safe and feasible",
            "criterions": [
                {
                    "exact_snippets": "Consent to undergo a biopsy prior to Cycle 1 Day 1 and Cycle 3 Day 1",
                    "criterion": "consent to biopsy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "prior to Cycle 1 Day 1",
                                "prior to Cycle 3 Day 1"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "if deemed medically safe and feasible",
                    "criterion": "medical safety and feasibility of biopsy",
                    "requirements": [
                        {
                            "requirement_type": "medical safety",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "feasibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must have received at least one prior systemic therapy (platinum/pemetrexed, immunotherapy or a combination thereof)",
            "criterions": [
                {
                    "exact_snippets": "Must have received at least one prior systemic therapy (platinum/pemetrexed, immunotherapy or a combination thereof)",
                    "criterion": "prior systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "prior systemic therapy"
                            }
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "platinum/pemetrexed",
                                "immunotherapy",
                                "combination thereof"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If of childbearing potential, must be willing to use highly effective mode of contraception for at least one month prior, during, and for 2 months after the end of active therapy",
            "criterions": [
                {
                    "exact_snippets": "If of childbearing potential",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must be willing to use highly effective mode of contraception for at least one month prior, during, and for 2 months after the end of active therapy",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "at least one month prior",
                                "during",
                                "for 2 months after the end of active therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ function, defined as",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease as defined primarily by the modified RECIST criteria for mesothelioma (at PI discretion RECIST v1.1 may be used)",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease as defined primarily by the modified RECIST criteria for mesothelioma (at PI discretion RECIST v1.1 may be used)",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "definition",
                            "expected_value": "modified RECIST criteria for mesothelioma or RECIST v1.1 at PI discretion"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate renal function defined as creatinine clearance ≥ 30ml/min (as calculated by Cockcroft-Gault Formula)",
            "criterions": [
                {
                    "exact_snippets": "Adequate renal function defined as creatinine clearance ≥ 30ml/min (as calculated by Cockcroft-Gault Formula)",
                    "criterion": "renal function (creatinine clearance)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "ml/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault Formula"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count ≥ 1.5K/mcL",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count ≥ 1.5K/mcL",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "/mcL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Currently participating in another study and receiving another study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 3 weeks of the first dose of treatment",
            "criterions": [
                {
                    "exact_snippets": "Currently participating in another study and receiving another study therapy",
                    "criterion": "participation in another study with study therapy",
                    "requirements": [
                        {
                            "requirement_type": "current participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has participated in a study of an investigational agent and received study therapy or used an investigational device within 3 weeks of the first dose of treatment",
                    "criterion": "prior participation in a study with investigational agent or device",
                    "requirements": [
                        {
                            "requirement_type": "prior participation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since participation",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Positive hepatitis B (hepatitis B virus [HBV]) surface antigen (HBsAg)",
            "criterions": [
                {
                    "exact_snippets": "Positive hepatitis B (hepatitis B virus [HBV]) surface antigen (HBsAg)",
                    "criterion": "hepatitis B surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* CD4 count < 350 cells/mm3 at screening",
            "criterions": [
                {
                    "exact_snippets": "CD4 count < 350 cells/mm3 at screening",
                    "criterion": "CD4 count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 350,
                                "unit": "cells/mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "o NOTE: Subjects with a prior history of HBV demonstrated by positive hepatitis B core antibody are eligible if they have at Screening 1) a negative HBsAg and 2) a HBV DNA (viral load) below the lower limit of quantification, per local testing. Patients who fit these criteria must use Hep B prophylaxis during treatment. Subjects with a positive HBsAg due to recent vaccination are eligible if HBV DNA (viral load) is below the lower limit of quantification, per local testing",
            "criterions": [
                {
                    "exact_snippets": "prior history of HBV demonstrated by positive hepatitis B core antibody",
                    "criterion": "prior history of HBV",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "demonstrated by",
                            "expected_value": "positive hepatitis B core antibody"
                        }
                    ]
                },
                {
                    "exact_snippets": "at Screening 1) a negative HBsAg",
                    "criterion": "HBsAg at Screening",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "at Screening ... 2) a HBV DNA (viral load) below the lower limit of quantification, per local testing",
                    "criterion": "HBV DNA (viral load) at Screening",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "lower limit of quantification"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who fit these criteria must use Hep B prophylaxis during treatment",
                    "criterion": "Hep B prophylaxis during treatment",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with a positive HBsAg due to recent vaccination are eligible if HBV DNA (viral load) is below the lower limit of quantification, per local testing",
                    "criterion": "positive HBsAg due to recent vaccination",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with a positive HBsAg due to recent vaccination are eligible if HBV DNA (viral load) is below the lower limit of quantification, per local testing",
                    "criterion": "HBV DNA (viral load) in subjects with positive HBsAg due to recent vaccination",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "lower limit of quantification"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receiving ART that may interfere with study treatment (consult sponsor for review of medication prior to enrollment)",
            "criterions": [
                {
                    "exact_snippets": "Receiving ART that may interfere with study treatment",
                    "criterion": "antiretroviral therapy (ART)",
                    "requirements": [
                        {
                            "requirement_type": "concomitant medication",
                            "expected_value": "ART that may interfere with study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Not agreeing to start ART and be on ART > 4 weeks plus having HIV viral load <400 copies/mL at end of 4-week period (to ensure ART is tolerated and HIV controlled)",
            "criterions": [
                {
                    "exact_snippets": "Not agreeing to start ART",
                    "criterion": "agreement to start ART",
                    "requirements": [
                        {
                            "requirement_type": "agreement",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "be on ART > 4 weeks",
                    "criterion": "duration on ART",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "HIV viral load <400 copies/mL at end of 4-week period",
                    "criterion": "HIV viral load",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 400,
                                "unit": "copies/mL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known psychiatric or substance abuse disorders that would interfere with the requirements of the trial within the opinion of the investigator",
            "criterions": [
                {
                    "exact_snippets": "Known psychiatric or substance abuse disorders",
                    "criterion": "psychiatric disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known psychiatric or substance abuse disorders",
                    "criterion": "substance abuse disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "would interfere with the requirements of the trial within the opinion of the investigator",
                    "criterion": "interference with trial requirements (due to psychiatric or substance abuse disorder)",
                    "requirements": [
                        {
                            "requirement_type": "interference_with_trial",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "investigator_opinion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, early stage prostate cancer, or in situ cervical cancer after definitive treatment",
            "criterions": [
                {
                    "exact_snippets": "Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, early stage prostate cancer, or in situ cervical cancer after definitive treatment",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "progression or treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": [
                                "basal cell carcinoma of the skin",
                                "squamous cell carcinoma of the skin",
                                "early stage prostate cancer",
                                "in situ cervical cancer after definitive treatment"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior cytotoxic/immunologic systemic therapy within 3 weeks prior to study Day 1 or has not recovered (i.e., CTCAE v5 ≥ Grade 1 at baseline; from clinically significant adverse events due to a previously administered agent (excluding Grade 2 neuropathy)",
            "criterions": [
                {
                    "exact_snippets": "Prior cytotoxic/immunologic systemic therapy within 3 weeks prior to study Day 1",
                    "criterion": "prior cytotoxic/immunologic systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "has not recovered (i.e., CTCAE v5 ≥ Grade 1 at baseline; from clinically significant adverse events due to a previously administered agent (excluding Grade 2 neuropathy)",
                    "criterion": "recovery from clinically significant adverse events due to a previously administered agent",
                    "requirements": [
                        {
                            "requirement_type": "CTCAE v5 grade at baseline",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        },
                        {
                            "requirement_type": "adverse event type",
                            "expected_value": "clinically significant"
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "excluding Grade 2 neuropathy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant is positive for human immunodeficiency virus (HIV), with 1 or more of the following:",
            "criterions": [
                {
                    "exact_snippets": "Participant is positive for human immunodeficiency virus (HIV)",
                    "criterion": "HIV status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior hypersensitivity to irinotecan or any components of sacituzumab govitecan-hziy",
            "criterions": [
                {
                    "exact_snippets": "Prior hypersensitivity to irinotecan",
                    "criterion": "hypersensitivity to irinotecan",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior hypersensitivity to ... any components of sacituzumab govitecan-hziy",
                    "criterion": "hypersensitivity to components of sacituzumab govitecan-hziy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), or coronary/peripheral artery bypass graft, or any acute coronary syndrome within 6 months of start of study drug",
            "criterions": [
                {
                    "exact_snippets": "Myocardial infarction ... within 6 months of start of study drug",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina ... within 6 months of start of study drug",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "stroke ... within 6 months of start of study drug",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "transient ischemic attack (TIA) ... within 6 months of start of study drug",
                    "criterion": "transient ischemic attack (TIA)",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "coronary/peripheral artery bypass graft ... within 6 months of start of study drug",
                    "criterion": "coronary artery bypass graft OR peripheral artery bypass graft",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any acute coronary syndrome within 6 months of start of study drug",
                    "criterion": "acute coronary syndrome",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant women or women who are breastfeeding or of childbearing potential and not using a highly effective method of birth control for at least one month prior to enrollment. If the risk of contraception exists, male and female subjects must use highly effective contraception throughout the study and for at least 60 days after last treatment. Highly effective contraception includes either 2 barrier methods (diaphragm, condom by the partner, copper intrauterine device, sponge, or spermicide), or 1 barrier method and 1 hormonal method (any oral, subcutaneous, intrauterine, or intramuscular registered and marketed contraceptive agent that contains an estrogen and/or a progesterone agent)",
            "criterions": [
                {
                    "exact_snippets": "Pregnant women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "women who are breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "women ... of childbearing potential and not using a highly effective method of birth control for at least one month prior to enrollment",
                    "criterion": "contraception use in women of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "population",
                            "expected_value": "women of childbearing potential"
                        },
                        {
                            "requirement_type": "contraception use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "month"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "prior to enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "If the risk of contraception exists, male and female subjects must use highly effective contraception throughout the study and for at least 60 days after last treatment",
                    "criterion": "contraception use during and after study",
                    "requirements": [
                        {
                            "requirement_type": "population",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        },
                        {
                            "requirement_type": "contraception use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": [
                                "throughout the study",
                                "after last treatment"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Highly effective contraception includes either 2 barrier methods ... or 1 barrier method and 1 hormonal method",
                    "criterion": "contraception method requirements",
                    "requirements": [
                        {
                            "requirement_type": "contraception method",
                            "expected_value": [
                                "2 barrier methods",
                                "1 barrier method and 1 hormonal method"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Congestive heart failure defined as New York Heart Association (NYHA) Class III-IV or hospitalization for congestive heart failure (any NYHA class) within 6 months of study Day 1",
            "criterions": [
                {
                    "exact_snippets": "Congestive heart failure defined as New York Heart Association (NYHA) Class III-IV",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "hospitalization for congestive heart failure (any NYHA class) within 6 months of study Day 1",
                    "criterion": "hospitalization for congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "time since hospitalization",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Positive hepatitis C antibody (anti-HCV)",
            "criterions": [
                {
                    "exact_snippets": "Positive hepatitis C antibody (anti-HCV)",
                    "criterion": "hepatitis C antibody (anti-HCV)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "o NOTE: Subjects with a prior history of HCV, who have completed antiviral treatment and have subsequently documented HCV RNA below the lower limit of quantification per local testing are eligible",
            "criterions": [
                {
                    "exact_snippets": "prior history of HCV",
                    "criterion": "history of HCV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "have completed antiviral treatment",
                    "criterion": "completion of antiviral treatment for HCV",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "have subsequently documented HCV RNA below the lower limit of quantification per local testing",
                    "criterion": "HCV RNA level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 0,
                                "unit": "lower limit of quantification (per local testing)"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* AIDS-defining opportunistic infection within 6 months of start of screening",
            "criterions": [
                {
                    "exact_snippets": "AIDS-defining opportunistic infection within 6 months of start of screening",
                    "criterion": "AIDS-defining opportunistic infection",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months from start of screening"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Total bilirubin ≤1.5 x upper limit of normal (ULN) if no liver metastases or <3 × ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases; subjects with Gilbert's syndrome can enroll if conjugated bilirubin is within normal limits",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin ≤1.5 x upper limit of normal (ULN) if no liver metastases",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": "no liver metastases"
                        }
                    ]
                },
                {
                    "exact_snippets": "Total bilirubin <3 × ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": [
                                "documented Gilbert's Syndrome (unconjugated hyperbilirubinemia)",
                                "liver metastases"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects with Gilbert's syndrome can enroll if conjugated bilirubin is within normal limits",
                    "criterion": "conjugated bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "within normal limits"
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": "Gilbert's syndrome"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}